Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of ABBV-CLS-628 in Adult ADPKD
jRCT2051250034Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial in autosomal dominant polycystic kidney disease (ADPKD) comparing ABBV-CLS-628 with Placebo (2 arms). Primary endpoint: Cumulative rate of change from baseline in total kidney volume at Week 96. Started Jul 2025; status: completed.
02
Drugs
ABBV-CLS-628
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on jRCT2051250034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250034.